DeepHealth Receives FDA Approval for New Breast Imaging Features
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
DeepHealth, a wholly owned subsidiary of RadNet, announces it has received FDA 510(k) clearances for two new Breast Suite functionalities: Breast Arterial Calcification Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease; Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls. ProFound Pro with prior exam integration will be brought to market as Mammo Dx. The two additions reinforce Breast Suite as the industry's most comprehensive end-to-end breast imaging AI suite-a modular, interoperable portfolio of applications addressing real-world clinical needs across breast cancer screening and diagnostic pathways. Both newly FDA cleared functionalities are now commercially available in the United States.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDNT
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.920
Low
86.00
Averages
90.17
High
95.00
Current: 68.920
Low
86.00
Averages
90.17
High
95.00
About RDNT
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network over of 435 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis & treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DeepHealth Receives FDA Clearance for New Breast Suite Features
- New Functionality Approved: DeepHealth's Breast Suite platform has received FDA 510(k) clearance for its Breast Arterial Calcification (BAC) Assessment feature, which automatically detects arterial calcifications on routine mammograms, potentially serving as an early indicator of cardiovascular disease, thereby enhancing early diagnosis capabilities.
- Cancer Detection Improvement: The FDA also cleared the prior exam integration for ProFound Pro, allowing automatic comparison of current and previous mammograms to track existing lesions and identify new ones, aimed at improving cancer detection rates and reducing patient recall rates, thus enhancing patient experience.
- Market Launch Plans: DeepHealth announced that both newly cleared functionalities are now commercially available in the U.S., which is expected to generate new revenue streams for the company and further solidify its market position in health informatics.
- Positive Stock Reaction: RadNet's stock closed at $58.16 on Wednesday and rose over 1% in pre-market trading on Thursday, reflecting market optimism regarding the new functionalities and their potential commercial value.
See More
DeepHealth Receives FDA Clearance for New Breast Imaging Features
- New Feature Approval: DeepHealth's Breast Arterial Calcification (BAC) Assessment tool has received FDA 510(k) clearance, enabling automatic identification of breast arterial calcifications during routine mammograms, which serves as an early indicator of cardiovascular disease, likely enhancing screening effectiveness and accuracy.
- Launch of Mammo Dx: The Mammo Dx, which integrates prior exam data, will allow radiologists to compare changes in breast tissue over time, aiding in the detection of subtle lesions that may go unnoticed in single-exam reads, thereby improving cancer detection rates and reducing false positives.
- Market Impact: The introduction of these two new functionalities positions DeepHealth's Breast Suite as the most comprehensive breast imaging AI suite in the industry, expected to enhance the company's competitiveness in breast cancer screening and diagnostics, addressing the growing clinical needs.
- Clinical Validation: The BAC Assessment demonstrated over 90% sensitivity and 88% specificity in clinical testing, and it is set to be widely deployed across RadNet imaging centers, further validating its effectiveness in real-world applications.
See More
DeepHealth Launches AI Reporting Platform for Radiologists
- Platform Launch: DeepHealth Inc. has officially launched Reporting Pro, a next-generation reporting platform that integrates speech recognition, AI findings, measurements, and quality checks, aimed at enhancing radiologists' efficiency amid rising imaging volumes and worsening workforce shortages.
- Clinical AI Integration: The platform pulls AI-generated findings and measurements from FDA-cleared and CE-marked DeepHealth and third-party tools directly into structured reports, thereby improving accuracy and consistency in reporting.
- Rapid Deployment: Reporting Pro supports the migration of existing templates and reporting preferences, allowing radiologists to maintain familiar workflows while adopting AI-enhanced tools, thus minimizing the learning curve and adaptation time.
- Unified Workflow: By combining speech recognition, AI findings, measurements, impressions, and quality assurance into a single connected reporting environment, Reporting Pro significantly reduces manual steps and data transfer, thereby improving efficiency and clinical quality.
See More
DeepHealth Launches AI Reporting Solution for Radiologists
- AI Reporting Solution Launch: DeepHealth has introduced Reporting Pro, an AI-integrated reporting tool designed to enhance radiologists' efficiency by automating reporting processes, which is expected to significantly reduce reporting times and directly improve the speed of treatment decisions for patients and physicians.
- Clinical AI Integration: The platform integrates FDA and CE-marked AI tools, enabling clinically relevant results to flow directly into structured reports, thereby enhancing accuracy and consistency, and helping radiologists work more efficiently in high-demand environments.
- Rapid Deployment and Adaptation: Reporting Pro supports seamless integration with existing workflows, allowing radiologists to maintain familiar templates and preferences while transitioning to a more intelligent reporting experience, ensuring a smooth technological shift.
- Market Expansion Plans: The solution is currently commercially available in the U.S. and the U.K., with plans to expand to Australia, South Africa, and select European markets by the end of the year, demonstrating DeepHealth's growth potential in the global radiology market.
See More
RadNet Seeks $200 Million Incremental Term Loan
- Financing Plan: RadNet is seeking to raise a $200 million incremental term loan through an amendment to its existing first-lien credit agreement, which will be added to the current term loan maturing on April 18, 2031, indicating the company's proactive approach to future funding needs.
- Use of Proceeds: The company expects to utilize the proceeds for future acquisitions, organic expansion initiatives, health system partnerships, and other general corporate purposes, highlighting its strategic intent for market expansion and business diversification.
- Market Conditions: RadNet noted that the financing remains subject to customary market and other conditions, reflecting the company's emphasis on risk management during the financing process.
- Transaction Timeline: If completed, the transaction is expected to close around mid-June, providing the necessary funding support for the company's future growth plans.
See More
Alpha Wave Global Reduces RadNet Stake by 63,147 Shares
- Stake Reduction Details: According to an SEC filing dated May 14, 2026, Alpha Wave Global reduced its RadNet position by 63,147 shares in Q1, with an estimated trade value of approximately $4.31 million, indicating a cautious outlook on the company.
- Ownership Proportion Change: Following the reduction, Alpha Wave Global's stake in RadNet stands at 478,304 shares, representing 3.38% of its 13F AUM, reflecting a diminished confidence in the company's future performance.
- Financial Performance Overview: RadNet's latest earnings report indicates a 22.1% year-over-year revenue increase to $575.6 million, with adjusted EBITDA rising 36.3% to $63.3 million, showcasing strong growth potential in its imaging business.
- Market Performance Analysis: As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, significantly underperforming the S&P 500 by 38.9 percentage points, prompting investors to closely monitor its future market performance.
See More
DeepHealth Receives FDA Clearance for New Breast Suite Features
- New Functionality Approved: DeepHealth's Breast Suite platform has received FDA 510(k) clearance for its Breast Arterial Calcification (BAC) Assessment feature, which automatically detects arterial calcifications on routine mammograms, potentially serving as an early indicator of cardiovascular disease, thereby enhancing early diagnosis capabilities.
- Cancer Detection Improvement: The FDA also cleared the prior exam integration for ProFound Pro, allowing automatic comparison of current and previous mammograms to track existing lesions and identify new ones, aimed at improving cancer detection rates and reducing patient recall rates, thus enhancing patient experience.
- Market Launch Plans: DeepHealth announced that both newly cleared functionalities are now commercially available in the U.S., which is expected to generate new revenue streams for the company and further solidify its market position in health informatics.
- Positive Stock Reaction: RadNet's stock closed at $58.16 on Wednesday and rose over 1% in pre-market trading on Thursday, reflecting market optimism regarding the new functionalities and their potential commercial value.
See More
DeepHealth Receives FDA Clearance for New Breast Imaging Features
- New Feature Approval: DeepHealth's Breast Arterial Calcification (BAC) Assessment tool has received FDA 510(k) clearance, enabling automatic identification of breast arterial calcifications during routine mammograms, which serves as an early indicator of cardiovascular disease, likely enhancing screening effectiveness and accuracy.
- Launch of Mammo Dx: The Mammo Dx, which integrates prior exam data, will allow radiologists to compare changes in breast tissue over time, aiding in the detection of subtle lesions that may go unnoticed in single-exam reads, thereby improving cancer detection rates and reducing false positives.
- Market Impact: The introduction of these two new functionalities positions DeepHealth's Breast Suite as the most comprehensive breast imaging AI suite in the industry, expected to enhance the company's competitiveness in breast cancer screening and diagnostics, addressing the growing clinical needs.
- Clinical Validation: The BAC Assessment demonstrated over 90% sensitivity and 88% specificity in clinical testing, and it is set to be widely deployed across RadNet imaging centers, further validating its effectiveness in real-world applications.
See More
DeepHealth Launches AI Reporting Platform for Radiologists
- Platform Launch: DeepHealth Inc. has officially launched Reporting Pro, a next-generation reporting platform that integrates speech recognition, AI findings, measurements, and quality checks, aimed at enhancing radiologists' efficiency amid rising imaging volumes and worsening workforce shortages.
- Clinical AI Integration: The platform pulls AI-generated findings and measurements from FDA-cleared and CE-marked DeepHealth and third-party tools directly into structured reports, thereby improving accuracy and consistency in reporting.
- Rapid Deployment: Reporting Pro supports the migration of existing templates and reporting preferences, allowing radiologists to maintain familiar workflows while adopting AI-enhanced tools, thus minimizing the learning curve and adaptation time.
- Unified Workflow: By combining speech recognition, AI findings, measurements, impressions, and quality assurance into a single connected reporting environment, Reporting Pro significantly reduces manual steps and data transfer, thereby improving efficiency and clinical quality.
See More
DeepHealth Launches AI Reporting Solution for Radiologists
- AI Reporting Solution Launch: DeepHealth has introduced Reporting Pro, an AI-integrated reporting tool designed to enhance radiologists' efficiency by automating reporting processes, which is expected to significantly reduce reporting times and directly improve the speed of treatment decisions for patients and physicians.
- Clinical AI Integration: The platform integrates FDA and CE-marked AI tools, enabling clinically relevant results to flow directly into structured reports, thereby enhancing accuracy and consistency, and helping radiologists work more efficiently in high-demand environments.
- Rapid Deployment and Adaptation: Reporting Pro supports seamless integration with existing workflows, allowing radiologists to maintain familiar templates and preferences while transitioning to a more intelligent reporting experience, ensuring a smooth technological shift.
- Market Expansion Plans: The solution is currently commercially available in the U.S. and the U.K., with plans to expand to Australia, South Africa, and select European markets by the end of the year, demonstrating DeepHealth's growth potential in the global radiology market.
See More
RadNet Seeks $200 Million Incremental Term Loan
- Financing Plan: RadNet is seeking to raise a $200 million incremental term loan through an amendment to its existing first-lien credit agreement, which will be added to the current term loan maturing on April 18, 2031, indicating the company's proactive approach to future funding needs.
- Use of Proceeds: The company expects to utilize the proceeds for future acquisitions, organic expansion initiatives, health system partnerships, and other general corporate purposes, highlighting its strategic intent for market expansion and business diversification.
- Market Conditions: RadNet noted that the financing remains subject to customary market and other conditions, reflecting the company's emphasis on risk management during the financing process.
- Transaction Timeline: If completed, the transaction is expected to close around mid-June, providing the necessary funding support for the company's future growth plans.
See More
Alpha Wave Global Reduces RadNet Stake by 63,147 Shares
- Stake Reduction Details: According to an SEC filing dated May 14, 2026, Alpha Wave Global reduced its RadNet position by 63,147 shares in Q1, with an estimated trade value of approximately $4.31 million, indicating a cautious outlook on the company.
- Ownership Proportion Change: Following the reduction, Alpha Wave Global's stake in RadNet stands at 478,304 shares, representing 3.38% of its 13F AUM, reflecting a diminished confidence in the company's future performance.
- Financial Performance Overview: RadNet's latest earnings report indicates a 22.1% year-over-year revenue increase to $575.6 million, with adjusted EBITDA rising 36.3% to $63.3 million, showcasing strong growth potential in its imaging business.
- Market Performance Analysis: As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, significantly underperforming the S&P 500 by 38.9 percentage points, prompting investors to closely monitor its future market performance.
See More
